Zhejiang Jiuzhou Pharmaceutical Co., Ltd. (Jiuzhou Pharma) is a publicly listed company (Stock code 603456) in China, focusing on the research/development and production of APIs/intermediates, providing products and CRO/CMO services to the customers. Adhering to the principle of "Live on high quality", Jiuzhou Pharma has established an efficient quality control system, and has acquired certifications for ISO9001, ISO14001 and GMP. Management of the company is conducted in the light of the GMP criterion, so as to effectively control the process and quality of raw materials, intermediates and finished products. APIs such as Carbamazepine, Ketoprofen etc. have passed GMP inspections and obtained COS certificates. Zhejiang Raybow Pharmaceutical Co. Ltd. is the CDMO division of Jiuzhou Pharma, focused on API development and manufacturing, which is located in the Linhai county, Taizhou City, Zhejiang province of China. The state of art manufacturing facility has R&D center, scale up plant and GMP production workshops. Raybow is a world leader in the development and manufacturing of Carbamazepine APIs capturing 40% international market.